Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.68 |
| ▸ | RAF1 | P04049 | 16/20 | 0.62 |
| ▸ | BRAF | P15056 | 15/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257833 | 0.89 | CSF1R (0.66) | CSF1RRAF1BRAFMAPK14 | |
| SCHEMBL4250376 | 0.87 | CSF1R (0.67) | CSF1RRAF1BRAFMAPK14 | |
| SCHEMBL4827472 | 0.87 | RAF1 (0.64) | CSF1RRAF1BRAFMAPK14 | |
| SCHEMBL27455134 | 0.86 | CSF1R (0.56) | CSF1RRAF1BRAFMAPK14 | |
| SCHEMBL4256187 | 0.86 | BRAF (0.63) | CSF1RRAF1BRAF | |
| SCHEMBL4253241 | 0.85 | BRAF (0.55) | CSF1RRAF1BRAF | |
| SCHEMBL25534818 | 0.85 | CSF1R (0.71) | CSF1RRAF1BRAFMAPK14 | |
| SCHEMBL1358527 | 0.82 | HDAC3 (0.58) | CSF1RBRAFMAPK14 | |
| SCHEMBL4823998 | 0.82 | BRAF (0.68) | CSF1RRAF1BRAFMAPK14 | |
| SCHEMBL1420016 | 0.82 | RAF1 (0.65) | CSF1RRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899329-B1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-05 | — | — | EP | disclosed |
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| WO-2007005673-A1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-01-11 | — | — | WO | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | disclosed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | CSF1R 430/4885RAF1 1655/4885BRAF 1768/4885 |
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | CSF1R 873/4885RAF1 2448/4885BRAF 3175/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | CSF1R 873/4885RAF1 2448/4885BRAF 3175/4885 |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | CSF1R 273/4885RAF1 1028/4885BRAF 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.